NEWS April 13, 2015

IMMUNE in Nature Biotechnology and Nature Reviews Drug Discovery

    B26 ADVERTISEMENT FEATURE IMMUNE Pharmaceuticals www.immunepharmaceuticals.com IMMUNE Pharmaceuticals   The next generation of antibody-drug conjugates With its second-generation antibody-drug conjugate platform, called NanomAb®, IMMUNE Pharmaceuticals hopes to grow through partnerships to co-develop new therapies. IMMUNE is also developing the clinical stage antibody, bertilimumab with a biomarker. IMMUNE Pharmaceuticals is a global company, and […]

Keep Reading

NEWS January 6, 2015

CEO Letter To Shareholders January 6, 2015

Dear Shareholders,
2014 was a year of transition for Immune Pharmaceuticals. We obtained a NASDAQ listing, raised over $20 million in equity, reduced past liabilities and strengthened our cash position.

Keep Reading

NEWS August 26, 2013

BioWorld Today: Immune Takes Road Less Traveled with Epicept Buy

By Marie Powers Staff Writer Privately held Immune Pharmaceuticals Ltd. swam against the tide of biotechs rushing to initial public offerings (IPO) by completing its merger with Epicept Corp., gaining access to the public markets and an expanded pipeline of cancer and pain compounds. The merged entity began trading last Wednesday on the Nasdaq OMX […]

Keep Reading

NEWS August 25, 2013

The Burrill Report: Immune Pharmaceuticals and EpiCept Combine

Israeli biotech takes reverse merger route to U.S. public listing. MARIE DAGHLIAN The Burrill Report “We look at bertilimumab as potentially the first treatment of inflammatory disease with a clearly identified biomarker—so personalized medicine.” Immune Pharmaceuticals has completed a reverse merger with the U.S. biotech EpiCept in an agreement valued at between $50 million and […]

Keep Reading

NEWS June 24, 2013

Next, Israel as the Boitech Nation

June 24,2013 http://blogs.timesofisrael.com/next-israel-as-the-biotech-nation/ while Israel is now world-renowned for its ability to start, grow and sell hi-tech, Internet and medical technology companies, biotech success is lagging despite Israel being # 2 behind the US in biotech patents per capita. Israeli scientists have contributed Intellectual Property to some of the world’s best-selling drugs, but the Israeli […]

Keep Reading